Fusidic Acid
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Fusidic Acid: From Staphylococcal Infections to Exposure Keratitis
One-Sentence Summary
Fusidic acid is a fusidane-class antibacterial with long-established use against staphylococcal skin and ocular surface infections. The TxGNN model predicts it may be effective for Exposure Keratitis, but this direction is currently supported by only 0 clinical trials and 1 case-series publication, and that publication does not directly study exposure keratitis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this dataset (fusidic acid’s general pharmacological use is staphylococcal skin/soft-tissue and ocular surface bacterial infections; no SAHPRA license record present) |
| Predicted New Indication | Exposure Keratitis |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L4 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, fusidic acid belongs to the fusidane class of antibacterials, which inhibit bacterial protein synthesis by blocking elongation factor G (EF-G); its efficacy against staphylococcal infections of the skin and ocular surface is well established, and mechanistically it may be applicable to exposure keratitis when the condition is complicated by secondary bacterial infection.
Exposure keratitis (corneal damage from inadequate eyelid closure) frequently becomes complicated by secondary bacterial colonization or infection, most commonly involving staphylococcal species. Fusidic acid ophthalmic gel formulations (e.g., Fucithalmic) are already established for ocular surface bacterial infections in other markets, which provides a plausible mechanistic bridge to this predicted use.
However, the only supporting literature in this evidence pack is a case series on Tsukamurella-associated ophthalmic infections — an opportunistic organism unrelated to typical staphylococcal exposure keratitis, and the paper does not study fusidic acid treatment of exposure keratitis directly. The rationale is therefore mechanistically plausible but not yet clinically demonstrated for this specific indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31246677 | 2019 | Case series | Cornea | Largest reported case series of Tsukamurella-associated ophthalmic infections (including post-enucleation implant infection); describes clinical spectrum, risk factors, treatment, and outcomes, but does not evaluate fusidic acid in exposure keratitis specifically |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for exposure keratitis is limited to a single indirectly-related case series (L4), no clinical trials exist for this indication, safety/labelling data for fusidic acid is entirely unavailable (a Blocking-severity gap), and the drug has no current SAHPRA registration (0 licenses, not marketed).
To proceed, the following is needed:
- SAHPRA-approved Professional Information (warnings, contraindications, precautions) — currently blocking
- Confirmed mechanism of action data from DrugBank
- Disease-specific clinical or preclinical evidence for fusidic acid in exposure keratitis (ideally with confirmed bacterial superinfection)
- Determination of registration/import pathway if this indication is to be pursued in South Africa
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.